{"id":53514,"date":"2026-01-10T21:37:44","date_gmt":"2026-01-10T13:37:44","guid":{"rendered":"https:\/\/flcube.com\/?p=53514"},"modified":"2026-01-10T21:37:45","modified_gmt":"2026-01-10T13:37:45","slug":"lillys-taltz-zepbound-combo-meets-primary-endpoint-in-psoriatic-arthritis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53514","title":{"rendered":"Lilly&#8217;s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis"},"content":{"rendered":"\n<p><strong>Eli Lilly (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>)<\/strong> announced <strong>positive topline results<\/strong> from the <strong>TOGETHER\u2011PsA<\/strong> open\u2011label Phase\u202f3b trial evaluating the <strong>concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide)<\/strong> versus Taltz alone in adults with <strong>active psoriatic arthritis (PsA)<\/strong> and obesity\/overweight with at least one weight\u2011related condition. The combination met the <strong>primary endpoint<\/strong> and all key secondary endpoints, demonstrating superiority at 36 weeks.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results-summary\">Clinical Trial Results Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial<\/strong><\/td><td>TOGETHER\u2011PsA Phase\u202f3b (first controlled incretin + biologic study)<\/td><\/tr><tr><td><strong>Regimen<\/strong><\/td><td>Taltz + Zepbound vs. Taltz monotherapy<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Adults with active PsA and obesity\/overweight<\/td><\/tr><tr><td><strong>Treatment Duration<\/strong><\/td><td>36 weeks<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>ACR50 + \u226510% weight reduction<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Primary Endpoint Achievement<\/strong>:<br><strong>31.7%<\/strong> of patients on <strong>Taltz + Zepbound<\/strong> achieved <strong>ACR50 + \u226510% weight loss<\/strong> vs. <strong>0.8%<\/strong> on <strong>Taltz alone<\/strong> (p&lt;.001).<\/p>\n\n\n\n<p><strong>Key Secondary Endpoint<\/strong>:<br><strong>33.5%<\/strong> on combination achieved <strong>ACR50<\/strong> vs. <strong>20.4%<\/strong> on monotherapy (p&lt;.05), representing a <strong>64% relative increase<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action\">Mechanism of Action<\/h2>\n\n\n\n<p><strong>Taltz (Ixekizumab)<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Monoclonal antibody<\/strong> that selectively binds <strong>interleukin\u201117A (IL\u201117A)<\/strong> cytokine<\/li>\n\n\n\n<li>Inhibits IL\u201117A interaction with IL\u201117 receptor, reducing <strong>inflammatory cascade<\/strong> in PsA<\/li>\n<\/ul>\n\n\n\n<p><strong>Zepbound (Tirzepatide)<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual GIP (glucose\u2011dependent insulinotropic polypeptide) and GLP\u20111 (glucagon\u2011like peptide\u20111) receptor agonist<\/strong><\/li>\n\n\n\n<li><strong>Only FDA\u2011approved dual incretin<\/strong> for obesity management<\/li>\n\n\n\n<li><strong>Reduces weight burden<\/strong>, thereby alleviating PsA disease activity<\/li>\n<\/ul>\n\n\n\n<p><strong>Synergistic Rationale<\/strong>: Treating obesity reduces <strong>mechanical joint stress<\/strong> and <strong>systemic inflammation<\/strong>, enhancing Taltz efficacy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-psoriatic-arthritis-amp-obesity\">Market Opportunity: Psoriatic Arthritis &amp; Obesity<\/h2>\n\n\n\n<p><strong>PsA Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US Prevalence<\/strong>: <strong>1\u202fmillion<\/strong> adults with PsA<\/li>\n\n\n\n<li><strong>Obesity Comorbidity<\/strong>: <strong>40\u201150%<\/strong> of PsA patients are obese or overweight<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: <strong>30\u201140%<\/strong> inadequate response to IL\u201117 inhibitors alone<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US PsA Market<\/strong>: <strong>$4.5\u202fbillion<\/strong> (2025), growing at <strong>8% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Obesity Management<\/strong>: <strong>$30\u201135\u202fbillion<\/strong> (2025), projected <strong>$70\u201180\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Combo Opportunity<\/strong>: <strong>$2\u20113\u202fbillion<\/strong> potential for adjunctive obesity therapy in PsA<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug\/Combo<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Taltz + Zepbound<\/strong><\/td><td><strong>Eli Lilly<\/strong><\/td><td>IL\u201117A inhibitor + GIP\/GLP\u20111<\/td><td>Phase\u202f3b<\/td><td><strong>First controlled combo study<\/strong><\/td><\/tr><tr><td><strong>Cosentyx<\/strong><\/td><td>Novartis<\/td><td>IL\u201117A inhibitor<\/td><td>Marketed<\/td><td>Monotherapy only<\/td><\/tr><tr><td><strong>Skyrizi<\/strong><\/td><td>AbbVie<\/td><td>IL\u201123 inhibitor<\/td><td>Marketed<\/td><td>Monotherapy only<\/td><\/tr><tr><td><strong>Ozempic<\/strong><\/td><td>Novo Nordisk<\/td><td>GLP\u20111 agonist<\/td><td>Marketed<\/td><td>Not studied in PsA combo<\/td><\/tr><tr><td><strong>Methotrexate<\/strong><\/td><td>Generic<\/td><td>DMARD<\/td><td>Standard of care<\/td><td>Limited efficacy in obesity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Advantage<\/strong>: Lilly is <strong>first to demonstrate<\/strong> that <strong>treating obesity reduces PsA burden<\/strong>, creating a <strong>new treatment paradigm<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-strategy\">Commercial Strategy<\/h2>\n\n\n\n<p><strong>Launch Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US<\/strong>: Potential <strong>sBLA filing<\/strong> in <strong>H2\u202f2026<\/strong>, approval <strong>2027<\/strong><\/li>\n\n\n\n<li><strong>Pricing<\/strong>: <strong>Premium pricing<\/strong> for combo (estimated <strong>$25,000\u201130,000\/year<\/strong> vs. Taltz alone at $18,000)<\/li>\n<\/ul>\n\n\n\n<p><strong>Patient Selection<\/strong>: Target <strong>PsA patients with BMI\u202f\u2265\u202f30<\/strong> or <strong>\u2265\u202f27 with comorbidities<\/strong> (~<strong>400,000<\/strong> eligible in US).<\/p>\n\n\n\n<p><strong>Reimbursement<\/strong>: Leverage <strong>obesity coverage expansion<\/strong> and <strong>PsA medical necessity<\/strong> for payer approval.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2027E<\/th><th>2028E<\/th><th>2029E<\/th><\/tr><\/thead><tbody><tr><td><strong>Eligible US Patients<\/strong><\/td><td>50,000<\/td><td>120,000<\/td><td>200,000<\/td><\/tr><tr><td><strong>Combo Penetration<\/strong><\/td><td>5%<\/td><td>12%<\/td><td>20%<\/td><\/tr><tr><td><strong>US Revenue (USD\u202fmillion)<\/strong><\/td><td>62.5<\/td><td>360<\/td><td>750<\/td><\/tr><tr><td><strong>Ex\u2011US Revenue<\/strong><\/td><td>12.5<\/td><td>90<\/td><td>210<\/td><\/tr><tr><td><strong>Total Revenue<\/strong><\/td><td><strong>75<\/strong><\/td><td><strong>450<\/strong><\/td><td><strong>960<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Peak Sales<\/strong>: <strong>$1.2\u20111.5\u202fbillion<\/strong> globally by 2030 for PsA\u2011obesity indication.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the Taltz\u2011Zepbound combo\u2019s regulatory pathway, market penetration, and revenue forecasts. Actual results may differ materially due to payer coverage decisions, competitive responses, and safety monitoring in broader populations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly (NYSE: LLY) announced positive topline results from the TOGETHER\u2011PsA open\u2011label Phase\u202f3b trial evaluating&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,199,911,86],"class_list":["post-53514","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-eli-lilly","tag-nyse-lly","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lilly&#039;s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly (NYSE: LLY) announced positive topline results from the TOGETHER\u2011PsA open\u2011label Phase\u202f3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis (PsA) and obesity\/overweight with at least one weight\u2011related condition. The combination met the primary endpoint and all key secondary endpoints, demonstrating superiority at 36 weeks.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53514\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lilly&#039;s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly (NYSE: LLY) announced positive topline results from the TOGETHER\u2011PsA open\u2011label Phase\u202f3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis (PsA) and obesity\/overweight with at least one weight\u2011related condition. The combination met the primary endpoint and all key secondary endpoints, demonstrating superiority at 36 weeks.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53514\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-10T13:37:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-10T13:37:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53514#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53514\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lilly&#8217;s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis\",\"datePublished\":\"2026-01-10T13:37:44+00:00\",\"dateModified\":\"2026-01-10T13:37:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53514\"},\"wordCount\":469,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Eli Lilly\",\"NYSE: LLY\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53514#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53514\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53514\",\"name\":\"Lilly's Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-10T13:37:44+00:00\",\"dateModified\":\"2026-01-10T13:37:45+00:00\",\"description\":\"Eli Lilly (NYSE: LLY) announced positive topline results from the TOGETHER\u2011PsA open\u2011label Phase\u202f3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis (PsA) and obesity\\\/overweight with at least one weight\u2011related condition. The combination met the primary endpoint and all key secondary endpoints, demonstrating superiority at 36 weeks.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53514#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53514\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53514#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly&#8217;s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lilly's Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly (NYSE: LLY) announced positive topline results from the TOGETHER\u2011PsA open\u2011label Phase\u202f3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis (PsA) and obesity\/overweight with at least one weight\u2011related condition. The combination met the primary endpoint and all key secondary endpoints, demonstrating superiority at 36 weeks.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53514","og_locale":"en_US","og_type":"article","og_title":"Lilly's Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis","og_description":"Eli Lilly (NYSE: LLY) announced positive topline results from the TOGETHER\u2011PsA open\u2011label Phase\u202f3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis (PsA) and obesity\/overweight with at least one weight\u2011related condition. The combination met the primary endpoint and all key secondary endpoints, demonstrating superiority at 36 weeks.","og_url":"https:\/\/flcube.com\/?p=53514","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-10T13:37:44+00:00","article_modified_time":"2026-01-10T13:37:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53514#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53514"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lilly&#8217;s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis","datePublished":"2026-01-10T13:37:44+00:00","dateModified":"2026-01-10T13:37:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53514"},"wordCount":469,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Eli Lilly","NYSE: LLY","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53514#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53514","url":"https:\/\/flcube.com\/?p=53514","name":"Lilly's Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-10T13:37:44+00:00","dateModified":"2026-01-10T13:37:45+00:00","description":"Eli Lilly (NYSE: LLY) announced positive topline results from the TOGETHER\u2011PsA open\u2011label Phase\u202f3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis (PsA) and obesity\/overweight with at least one weight\u2011related condition. The combination met the primary endpoint and all key secondary endpoints, demonstrating superiority at 36 weeks.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53514#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53514"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53514#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lilly&#8217;s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53514"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53514\/revisions"}],"predecessor-version":[{"id":53517,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53514\/revisions\/53517"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}